The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Smith & Nephew (NYSE:SNN) saw its $85 million patent win against Arthrex Inc. overturned this week, after an Oregon judge ruled that Arthrex didn’t infringe on SNN’s surgical anchor patents.
The latest round in the 7-year-old patent lawsuit found that "no reasonable jury could possibly find that Arthrex infringed in this case," including via indirect infringement.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Argentum Medical is suing its former intellectual property law firm after it lost a patent infringement suit it filed against Noble Biomaterials.
The U.S. Supreme Court heard oral arguments this week in a case that could have wide-reaching implications for health care: Whether medical patents should be allowed.
At issue is the specter of doctors being sued for patent infringement based on treatment decisions derived from the scientific research underpinning the patent.
C.R. Bard Inc. (NYSE:BCR) plans to cut 50 jobs from its Queensbury, N.Y.-based manufacturing plant.
The 50 positions could be relocated outside the U.S., according to the Glen Falls, N.Y.-based Post Star. That would leave the Queensbury plant with roughly 770 employees.
A nasty patent spat between Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. and Spectralytics, which a jury decided in the latter’s favor to the tune of $22.4 million, went another round this week after a judge added $500,000 to the damages award.
A nasty patent spat between Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. and Spectralytics, which a jury decided in the latter’s favor to the tune of $22.4 million, went another round this week after a judge added $500,000 to the damages award.
Histogen Inc. is declaring victory after a Southern California judge’s decision that its technique for growing human skin cells does not infringe a pair of patents covering SkinMedica’s NouriCel product line.
It’s the second time San Diego-based Histogen, which is primarily focused on regenerative medicine solutions for wound care, has touted a win from U.S. District Court Judge Janis Sammartino. The judge sided with Histogen on how the patents’ claims should be construed.
Dr. Samuel DeMaio
A Texas doctor accused of unnecessary stenting has slipped three of four trials against him with his license to practice in the Lone Star State intact.
Dr. Samuel DeMaio, accused last year of standard-of-care violations related to nine patients who allegedly received un-needed stents, angiograms and ICD implants, had pushed for a trial after mediation efforts with the Texas Medical Board collapsed.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
